-
1 Comment
CARDIOVASC SYS - Frankfurt Stock Exchang is currently in a long term uptrend where the price is trading 8.5% above its 200 day moving average.
From a valuation standpoint, the stock is 51.9% cheaper than other stocks from the Other sector with a price to sales ratio of 6.1.
CARDIOVASC SYS - Frankfurt Stock Exchang's total revenue sank by 6.1% to $64M since the same quarter in the previous year.
Its net income has increased by 98.4% to $-56K since the same quarter in the previous year.
Finally, its free cash flow fell by 73.5% to $835K since the same quarter in the previous year.
Based on the above factors, CARDIOVASC SYS - Frankfurt Stock Exchang gets an overall score of 3/5.
| CurrencyCode | EUR |
|---|---|
| Exchange | F |
| ISIN | US1416191062 |
| Sector | Healthcare |
| Industry | Medical Devices |
| PE Ratio | None |
|---|---|
| Target Price | None |
| Dividend Yield | 0.0% |
| Beta | 0.74 |
| Market Cap | 765M |
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota. As of April 27, 2023, Cardiovascular Systems, Inc. operates as subsidiary of Abbott Laboratories (NYSE:ABT).
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for R7Y1.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
